On March 26th, 2018, the National Hemophilia Foundation received information from Genentech’s Clinical Development Lead regarding reports of the death of patients utilizing Hemlibra (emicizumab). Genentech has confirmed that a total of 5 adult patient deaths have occurred while using Hemlibra. Genentech has limited information about the circumstances surrounding these deaths. However, as reported by Genentech, these deaths have all been deemed unrelated to Hemlibra by the investigator or treating physician.

For patients, concerned community members, and healthcare providers, Genentech’s medical communication line is available at 1.800.821.8590. NHF will continue to keep our community members informed on the latest information as it becomes available.

Recent News